ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurdow, R.
Right arrow Articles by Kalthoff, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurdow, R.
Right arrow Articles by Kalthoff, H.

Ann Thorac Surg 2002;73:905-910
© 2002 The Society of Thoracic Surgeons

Original article: general thoracic

Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer

Roland Kurdow, MD*a,1, Arnd S. Boehle, MDa,1, Sieglinde Hayea, Lars Boenickea, Bodo Schniewind, MDa, Peter Dohrmann, PhDa, Holger Kalthoff, PhDa

a Department for General Surgery and Thoracic Surgery, University Hospital, Christian-Albrechts-University, Kiel, Germany

Accepted for publication October 18, 2001.

* Address reprint requests to Dr Kurdow, Department for General and Thoracic Surgery, University Hospital, Christian-Albrechts-University, Arnold-Heller Strasse 7, 24105 Kiel, Germany
e-mail: rkurdow{at}surgery.uni-kiel.de

Background. Therapy failures have been reported for retroviral gene transfer of herpes simplex virus thymidine kinase (HSV-TK) gene followed by systemic ganciclovir application in human lung cancer. Use of the HSV-TK mutant TK30 in combination with a VSV-G pseudotyped retroviral vector was found to enhance the efficacy of prodrug therapy. The present study evaluated this therapeutic strategy in human non-small cell lung cancer cell lines in a preclinical murine xenotransplant model.

Methods. Intrathoracally tumors induced by HSV-TK30 transduced non-small cell lung cancer cell lines Colo 699 (adenocarcinoma) and KNS 62 (squamous cell carcinoma) were monitored for local tumor growth, survival, and metastases. So-called bystander effects were investigated in tumors consisting of as little as 25% TK30 transfected cells and by analysis of gap junctional protein connexin-43 expression.

Results. Survival was significantly prolonged, and tumor growth and pleural metastases were reduced in HSV-TK30-positive tumors of both cell lines. A significant therapeutic effect in bystander experiments was observed in squamous cell carcinoma. This was correlated with higher expression of connexin-43.

Conclusions. Delivery of HSV-TK30 in a VSV-G pseudotyped retroviral vector and subsequent ganciclovir application provided therapeutic efficacy. Despite of low transduction rates achievable in gene transfer in situ, prodrug therapy appears to be feasible in tumor cells with efficient bystander effects.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
W. R. Smythe
Gene therapy for thoracic disease: practice, promise, and pragmatism
Ann. Thorac. Surg., March 1, 2002; 73(3): 704 - 706.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The Society of Thoracic Surgeons.